Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.

Thrombosis research - 1 Jun 2015

Hokimoto Seiji, Akasaka Tomonori, Tabata Noriaki, Arima Yuichiro, Tsujita Kenichi, Sakamoto Kenji, Kaikita Koichi, Morita Kazunori, Kumagae Naoki, Yamamoto Eiichiro, Oniki Kentaro, Nakagawa Kazuko, Ogawa Hisao

Abstract excerpt

OBJECTIVES: The aim of this study was to investigate the effect of CYP2C19 polymorphism and co-therapy with esomeprazole on the antiplatelet efficacy of clopidogrel. BACKGROUND: The antiplatelet efficacy of clopidogrel depends on CYP2C19 polymorphism or the co-administration of some kind of proton pump inhibitor (PPI). METHODS: CYP2C19 genotype and the residual platelet reactivity (RPR) were measured in 361...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspirin
Share to Blood Platelets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Coronary Disease

Share to Cytochrome P-450 CYP2C19

Share to Platelet Aggregation Inhibitors

Share to Proton Pump Inhibitors

Share to Ticlopidine

Source

Identifiers

PMID: 25891840
DOI: 10.1016/j.thromres.2015.03.033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.PMID 25891840Read ↗

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.Semantic proximity Read ↗

Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.Semantic proximity Read ↗

CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.Semantic proximity Read ↗

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Adverse events in cardiovascular disease patients taking clopidogrel: impact of CYP2C19 genotype polymorphismsSemantic proximity Read ↗

Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.Semantic proximity Read ↗

Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.Semantic proximity Read ↗

The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.Semantic proximity Read ↗

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.Semantic proximity Read ↗

A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.